Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

Wellington S Silva Júnior¹, Maria das Graças C Souza², Luiz Guilherme Kraemer-Aguiar^{2

3

4}

Affiliations

¹ Endocrinology Discipline, Faculty of Medicine, Center of Natural, Human, Health, and Technology Sciences, Federal University of Maranhão (UFMA), Pinheiro, MA, Brazil.
² Laboratory for Clinical and Experimental Research on Vascular Biology (BioVasc), Biomedical Center, State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
³ Postgraduate Program in Clinical and Experimental Physiopathology (FISCLINEX), Faculty of Medical Sciences, UERJ, Rio de Janeiro, RJ, Brazil.
⁴ Endocrinology, Department of Internal Medicine, Faculty of Medical Sciences, UERJ, Rio de Janeiro, RJ, Brazil.

PMID: 30652100
PMCID: PMC6295385
DOI: 10.21037/hbsn.2018.10.05

Editorial

Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

Wellington S Silva Júnior et al. Hepatobiliary Surg Nutr. 2018 Dec.

. 2018 Dec;7(6):499-500.

doi: 10.21037/hbsn.2018.10.05.

Authors

Wellington S Silva Júnior¹, Maria das Graças C Souza², Luiz Guilherme Kraemer-Aguiar^{2

3

4}

Affiliations

¹ Endocrinology Discipline, Faculty of Medicine, Center of Natural, Human, Health, and Technology Sciences, Federal University of Maranhão (UFMA), Pinheiro, MA, Brazil.
² Laboratory for Clinical and Experimental Research on Vascular Biology (BioVasc), Biomedical Center, State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
³ Postgraduate Program in Clinical and Experimental Physiopathology (FISCLINEX), Faculty of Medical Sciences, UERJ, Rio de Janeiro, RJ, Brazil.
⁴ Endocrinology, Department of Internal Medicine, Faculty of Medical Sciences, UERJ, Rio de Janeiro, RJ, Brazil.

PMID: 30652100
PMCID: PMC6295385
DOI: 10.21037/hbsn.2018.10.05

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cited by

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Hattori S, Nomoto K, Suzuki T, Hayashi S. Hattori S, et al. Diabetol Metab Syndr. 2021 Mar 10;13(1):28. doi: 10.1186/s13098-021-00644-5. Diabetol Metab Syndr. 2021. PMID: 33691757 Free PMC article.
DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?
Perry C, Kapur N, Barrett TA. Perry C, et al. Inflamm Bowel Dis. 2020 Oct 23;26(11):1720-1721. doi: 10.1093/ibd/izz320. Inflamm Bowel Dis. 2020. PMID: 31913471 Free PMC article. No abstract available.
CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease.
Godoy-Matos AF, Valério CM, Júnior WSS, de Araujo-Neto JM, Sposito AC, Suassuna JHR. Godoy-Matos AF, et al. Diabetol Metab Syndr. 2025 Jun 16;17(1):218. doi: 10.1186/s13098-025-01796-4. Diabetol Metab Syndr. 2025. PMID: 40524210 Free PMC article. Review.
Gut Hormones and Inflammatory Bowel Disease.
Weng J, Lo CC. Weng J, et al. Biomolecules. 2025 Jul 14;15(7):1013. doi: 10.3390/biom15071013. Biomolecules. 2025. PMID: 40723884 Free PMC article. Review.
Distal mutation V486M disrupts the catalytic activity of DPP4 by affecting the flap of the propeller domain.
Li TT, Peng C, Wang JQ, Xu ZJ, Su MB, Li J, Zhu WL, Li JY. Li TT, et al. Acta Pharmacol Sin. 2022 Aug;43(8):2147-2155. doi: 10.1038/s41401-021-00818-x. Epub 2021 Dec 14. Acta Pharmacol Sin. 2022. PMID: 34907358 Free PMC article.

See all "Cited by" articles

References

1. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18. 10.1111/j.1463-1326.2010.01306.x - DOI - PubMed
1. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011;55:10-6. 10.1016/j.vph.2011.05.001 - DOI - PubMed
1. Ghorpade DS, Ozcan L, Zheng Z, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 2018;555:673-7. 10.1038/nature26138 - DOI - PMC - PubMed
1. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-25. 10.2337/db10-1707 - DOI - PMC - PubMed
1. da Silva Júnior WS, Souza MD, Nogueira Neto JF, et al. Constitutive DPP4 activity, inflammation, and microvascular reactivity in subjects with excess body weight and without diabetes. Microvasc Res 2018;120:94-9. 10.1016/j.mvr.2018.07.005 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

Affiliations

Dipeptidyl peptidase 4 (DPP4), adipose inflammation, and insulin resistance: is it time to look to the hepatocyte?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous